Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Clin Oncol
    October 2025
  1. LI J, Huang R, Hu H
    Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501476. doi: 10.1200/JCO-25-01476.
    >> Share

  2. TRAN PT, Wang JH, Tang C, Kiess AP, et al
    Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501855. doi: 10.1200/JCO-25-01855.
    >> Share

    August 2025
  3. MENNE GURICOVA K, Draulans C, Pos FJ, Kerkmeijer LGW, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.
    J Clin Oncol. 2025 Aug 4:JCO2500274. doi: 10.1200/JCO-25-00274.
    >> Share

    July 2025
  4. SAYEGH N, Ozay ZI, Zhang T, Agarwal N, et al
    Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer.
    J Clin Oncol. 2025 Jul 28:JCO2501009. doi: 10.1200/JCO-25-01009.
    >> Share

  5. LEONE G, Wong YNS, Jones RJ, Sankey P, et al
    Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study.
    J Clin Oncol. 2025 Jul 28:JCO2402637. doi: 10.1200/JCO-24-02637.
    >> Share

    June 2025
  6. WANG JH, Sherry AD, Bazyar S, Sutera P, et al
    Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
    J Clin Oncol. 2025;43:2059-2068.
    >> Share

  7. STEIN MN, Vinceneux A, Robbrecht D, Doger B, et al
    Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study.
    J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678.
    >> Share

    May 2025
  8. HASSANZADEH C, Kuban D, Pasyar S, Bassett R, et al
    Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.
    J Clin Oncol. 2025 May 14:JCO2402057. doi: 10.1200/JCO-24-02057.
    >> Share

  9. GARJE R, Riaz IB, Naqvi SAA, Rumble RB, et al
    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 May 2:JCO2500007. doi: 10.1200/JCO-25-00007.
    >> Share

    April 2025
  10. KUNZ N, Kemper C
    Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment.
    J Clin Oncol. 2025 Apr 22:JCO2500457. doi: 10.1200/JCO-25-00457.
    >> Share

  11. ARMSTRONG AJ, Liu VYT, Selvaraju RR, Chen E, et al
    Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
    J Clin Oncol. 2025 Apr 16:JCO2400365. doi: 10.1200/JCO.24.00365.
    >> Share

    March 2025
  12. AGGARWAL RR, Vuky J, VanderWeele D, Rettig M, et al
    Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989.
    >> Share

  13. SLOVIN SF
    Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
    J Clin Oncol. 2025 Mar 13:JCO2402402. doi: 10.1200/JCO-24-02402.
    >> Share

  14. PETRYLAK DP, Ratta R, Matsubara N, Korbenfeld E, et al
    Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
    J Clin Oncol. 2025 Mar 5:JCO2401283. doi: 10.1200/JCO-24-01283.
    >> Share

    January 2025
  15. SAAD F, Vjaters E, Testa I, Haresh KP, et al
    Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402742. doi: 10.1200/JCO-24-02742.
    >> Share

  16. MITTAL A, Linford G, Gyawali B
    Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402314. doi: 10.1200/JCO-24-02314.
    >> Share

  17. YU EY, Rumble RB, Agarwal N, Cheng HH, et al
    Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2025 Jan 9:JCO2402608. doi: 10.1200/JCO-24-02608.
    >> Share

    December 2024
  18. DIZMAN N, Necchi A
    Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial.
    J Clin Oncol. 2024 Dec 13:JCO2402444. doi: 10.1200/JCO-24-02444.
    >> Share

  19. ARONSON WJ, Grogan T, Liang P, Jardack P, et al
    High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
    J Clin Oncol. 2024 Dec 13:JCO2400608. doi: 10.1200/JCO.24.00608.
    >> Share

    October 2024
  20. BROOKS JD
    Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
    J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941.
    >> Share

    September 2024
  21. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage Reirradiation.
    J Clin Oncol. 2024 Sep 17:JCO2401067. doi: 10.1200/JCO.24.01067.
    >> Share

  22. SAAD F, Vjaters E, Shore N, Olmos D, et al
    Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
    J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798.
    >> Share

  23. TOMBAL B, Giannarini G
    Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How.
    J Clin Oncol. 2024 Sep 6:JCO2401134. doi: 10.1200/JCO.24.01134.
    >> Share

    July 2024
  24. VIGNESWARAN HT, Eklund M, Discacciati A, Nordstrom T, et al
    Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
    J Clin Oncol. 2024 Jul 22:JCO2400152. doi: 10.1200/JCO.24.00152.
    >> Share

    June 2024
  25. GARCIA JA, Spratt DE
    Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?
    J Clin Oncol. 2024 Jun 14:JCO2400210. doi: 10.1200/JCO.24.00210.
    >> Share

    May 2024
  26. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445.
    >> Share

  27. EINSTEIN DJ, Regan MM, Stevens JS, McDermott DF, et al
    Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
    J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279.
    >> Share

  28. SPRATT DE
    Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
    J Clin Oncol. 2024 May 14:JCO2302689. doi: 10.1200/JCO.23.02689.
    >> Share

  29. SAYAN M, Chen MH, Loffredo M, McMahon E, et al
    Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
    J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
    >> Share

    April 2024
  30. EKANGER C, Helle SI, Reisaeter L, Hysing LB, et al
    Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
    J Clin Oncol. 2024 Apr 23:JCO2301391. doi: 10.1200/JCO.23.01391.
    >> Share


  31. Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454.
    >> Share

    March 2024
  32. YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
    Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
    >> Share

  33. MADAN RA, Yu EY, Posadas EM, Lee RJ, et al
    Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727.
    >> Share

  34. FALLAH J, Xu J, Weinstock C, Gao X, et al
    Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105.
    >> Share

  35. KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al
    Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
    J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762.
    >> Share

  36. HEISS BL, Chang E, Gao X, Truong T, et al
    US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2024 Mar 7:JCO2302182. doi: 10.1200/JCO.23.02182.
    >> Share

    January 2024
  37. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    >> Share

  38. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    >> Share

  39. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    >> Share

  40. DENMEADE SR
    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.
    >> Share

    December 2023
  41. FALLAH J, Xu J, Weinstock C, Brave MH, et al
    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868.
    >> Share

    November 2023
  42. MATEO J, de Bono JS, Fizazi K, Saad F, et al
    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
    >> Share

  43. ROY S, Romero T, Michalski JM, Feng FY, et al
    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
    J Clin Oncol. 2023;41:5005-5014.
    >> Share

  44. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128.
    >> Share

  45. TAGAWA ST, Thomas C, Sartor AO, Sun M, et al
    Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
    J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573.
    >> Share

    October 2023
  46. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    >> Share

  47. MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al
    Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
    J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502.
    >> Share

    September 2023
  48. FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al
    Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
    J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985.
    >> Share

  49. STAR J, Bandi P, Siegel RL, Han X, et al
    Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
    J Clin Oncol. 2023;41:4352-4359.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016